Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2015; 36(02): 133-136
DOI: 10.4103/0971-5851.158852
CONFERENCE REVIEW

Updates from Gastrointestinal ASCO 2015

Shaheenah Dawood
Department of Medical Oncology, Dubai Hospital, UAE
› Author Affiliations
› Further Information
Also available at
  PDF Download Permissions and Reprints

Abstract

This year at ASCO GI we saw important data presented that has continued to shape the way we treat GI malignancies. Several important questions were addressed. Can we avoid surgery among patients with rectal tumors? Data from a provocative retrospective study indicated that certain subgroups of patients might not need surgery thereby preserving the rectum without compromising survival outcome. What is the role of ramicurumab among patients with advanced colorectal cancers? Data from the phase III RAISE trial revealed that the addition of ramicurumab to second line therapy significantly improved median overall survival. What is the role of immunotherapy in GI malignancies? Interesting results from the KEYNOTE-012 trial was presented that looked at the efficacy of pembriluzumab among patients with advanced gastric cancer with the investigators reporting interesting results of an objective response rate of 22.1% and a 6 months progression free survival of 24%. In this review we will briefly present these and other important highlights of the ASCO GI meeting.

Keywords

Colorectal cancer - pancreatic cancer - gastric cancer


Publication History

Article published online:
12 July 2021

© 2015. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Ng K, Venook AP, Sato K, Hollis BW, Niedzwiecki D, Ye C, et al. Vitamin D status and survival of metastatic colorectal cancer patients: Results from CALGB/SWOG 80405 (Alliance). ASCO Gastrointestinal Cancers Symposium; 2015. [Abstract 507].
  • 2 Cremolini C, Loupakis F, Masi G, Zagonel V, Bergamo F, Salvatore L, et al. FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (mCRC): Updated survival results of the phase III TRIBE trial by the GONO group. ASCO Gastrointestinal Cancers Symposium; 2015. [Abstract 657].
  • 3 Tabernero J, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, et al. RAISE: A randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (pts) with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab (bev), oxaliplatin (ox), and a fluoropyrimidine (fp). ASCO Gastrointestinal Cancers Symposium; 2015. [Abstract 512].
  • 4 Smith JJ, Chow OS, Eaton A, Widmar M, Nash GM, Temple LKF, et al. Organ preservation in patients with rectal cancer with clinical complete response after neoadjuvant therapy. ASCO Gastrointestinal Cancers Symposium; 2015. [Abstract 509].
  • 5 Chen LT, Von Hoff DD, Li CP, Wang-Gillam A, Bodoky G, Dean AP, et al. Expanded analyses of napoli-1: Phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy. ASCO Gastrointestinal Cancers Symposium; 2015. [Abstract 234].
  • 6 Phan AT, Caplin ME, Pavel ME, Cwikla JB, Raderer M, Sedla D, et al. Effects of lanreotideautogel/depot (LAN) in pancreatic neuroendocrine tumors (pNETs): A subgroup analysis from the CLARINET study. ASCO Gastrointestinal Cancers Symposium; 2015. [Abstract 233].
  • 7 Shah MA, Cho JY, Tan IB, Tebbutt NC, Yen C-J, Kang A, et al. Randomized phase II study of FOLFOX +/-MET inhibitor, onartuzumab (O), in advanced gastroesophageal adenocarcinoma (GEC). ASCO Gastrointestinal Cancers Symposium; 2015. [Abstract 2].
  • 8 Kwak EL, LoRusso P, Hamid O, Janku F, Kittaneh M, Catenacci DVT, et al. Clinical activity of AMG 337, an oral MET kinase inhibitor, in adult patients (pts) with MET-amplified gastroesophageal junction (GEJ), gastric (G), or esophageal (E) cancer. ASCO Gastrointestinal Cancers Symposium; 2015. [Abstract 1].
  • 9 Muro K, Bang Y-J, Shankaran V, Geva R, Catenacci DVT, Gupta S, et al. Relationship between PD-L1 expression and clinical outcomes in patients (Pts) with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK-3475) in KEYNOTE-012. ASCO Gastrointestinal Cancers Symposium; 2015. [Abstract 3].
  • 10 Mariette C, Meunier B, Pezet D, Dalban C, Collet D, Thomas PA, et al. Hybrid minimally invasive versus open oesophagectomy for patients with oesophageal cancer: A multicenter, open-label, randomized phase III controlled trial, the MIRO trial. ASCO Gastrointestinal Cancers Symposium; 2015. [Abstract 5].
  • 11 Penniment MG. Full report of the TROG 03.01, NCIC CTG ES2 multinational phase III study in advanced esophageal cancer comparing palliation of dysphagia and quality of life in patients treated with radiotherapy or chemoradiotherapy. ASCO Gastrointestinal Cancers Symposium; 2015. [Abstract].
  • 12 Zhu AX, Ryoo BY, Yen CJ, Kudo M, Poon RT-P, Pastorelli D, et al. Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of patients with elevated α-fetoprotein (AFP) from the randomized phase III REACH study. ASCO Gastrointestinal Cancers Symposium; 2015. [Abstract 232].